Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine for Reversal of Neuromuscular Blockade in Abdominal Surgery
NCT00675792Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2008
- Primary completion
- Sep 2008
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
Phase 3, randomised, single-blind trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Merck & Co. Primary endpoint: Residual Neuromuscular Blockade Evidenced by T4/T1 Ratio at the Time of Tracheal Extubation. Started May 2008; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT00675792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00675792.